With Frederick Ball, Jiazhong (Jason) Luo
The FDA recently updated its MAPP 5240.3 on Prioritization of the Review of Original ANDAs, Amendments and Supplements to Revision 2, adding a new category of expedited review of abbreviated new drug application submissions for "sole-source" drug products.